AR126552A1 - Composición farmacéutica para prevenir o tratar la esclerosis sistémica - Google Patents
Composición farmacéutica para prevenir o tratar la esclerosis sistémicaInfo
- Publication number
- AR126552A1 AR126552A1 ARP220101953A ARP220101953A AR126552A1 AR 126552 A1 AR126552 A1 AR 126552A1 AR P220101953 A ARP220101953 A AR P220101953A AR P220101953 A ARP220101953 A AR P220101953A AR 126552 A1 AR126552 A1 AR 126552A1
- Authority
- AR
- Argentina
- Prior art keywords
- pharmaceutical composition
- preventing
- systemic sclerosis
- treating systemic
- treating
- Prior art date
Links
- 239000008194 pharmaceutical composition Substances 0.000 title abstract 3
- 201000009594 Systemic Scleroderma Diseases 0.000 title 1
- 206010042953 Systemic sclerosis Diseases 0.000 title 1
- 206010016654 Fibrosis Diseases 0.000 abstract 2
- 230000004761 fibrosis Effects 0.000 abstract 2
- 230000009885 systemic effect Effects 0.000 abstract 2
- 150000001875 compounds Chemical class 0.000 abstract 1
- 230000002265 prevention Effects 0.000 abstract 1
- 150000003839 salts Chemical class 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
- A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
- A61K31/454—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. pimozide, domperidone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
Abstract
La composición farmacéutica de acuerdo con la presente invención se puede utilizar útilmente para la prevención o el tratamiento de la fibrosis sistémica. Reivindicación 1: Una composición farmacéutica para prevenir o tratar la fibrosis sistémica que comprende un compuesto representado por la fórmula (1), o una sal farmacéuticamente aceptable del mismo.
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| KR20210097163 | 2021-07-23 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| AR126552A1 true AR126552A1 (es) | 2023-10-18 |
Family
ID=84979421
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ARP220101953A AR126552A1 (es) | 2021-07-23 | 2022-07-22 | Composición farmacéutica para prevenir o tratar la esclerosis sistémica |
Country Status (7)
| Country | Link |
|---|---|
| KR (1) | KR20230015858A (es) |
| CN (1) | CN117693343A (es) |
| AR (1) | AR126552A1 (es) |
| AU (1) | AU2022316021A1 (es) |
| CA (1) | CA3225425A1 (es) |
| TW (1) | TW202320772A (es) |
| WO (1) | WO2023003416A1 (es) |
Family Cites Families (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CA2861840C (en) * | 2012-01-13 | 2020-12-15 | President And Fellows Of Harvard College | Halofuginol derivatives and their use in cosmetic and pharmaceutical compositions |
| AR110963A1 (es) | 2017-02-07 | 2019-05-22 | Dae Woong Pharma | Compuestos heterocíclicos, su método de preparación y composición farmacéutica que los comprende |
-
2022
- 2022-07-22 CN CN202280051585.2A patent/CN117693343A/zh active Pending
- 2022-07-22 TW TW111127532A patent/TW202320772A/zh unknown
- 2022-07-22 KR KR1020220090701A patent/KR20230015858A/ko unknown
- 2022-07-22 AR ARP220101953A patent/AR126552A1/es unknown
- 2022-07-22 CA CA3225425A patent/CA3225425A1/en active Pending
- 2022-07-22 WO PCT/KR2022/010751 patent/WO2023003416A1/ko active Application Filing
- 2022-07-22 AU AU2022316021A patent/AU2022316021A1/en active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| WO2023003416A1 (ko) | 2023-01-26 |
| AU2022316021A1 (en) | 2024-01-18 |
| CN117693343A (zh) | 2024-03-12 |
| CA3225425A1 (en) | 2023-01-26 |
| TW202320772A (zh) | 2023-06-01 |
| KR20230015858A (ko) | 2023-01-31 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CO2019015090A2 (es) | Métodos de tratamiento para la fibrosis cística | |
| CO2023000199A2 (es) | Péptidos funcionalizados como agentes antivirales | |
| CL2020001752A1 (es) | Derivado de oxi-fluoropiperidina como inhibidor de quinasa. | |
| CO2020007156A2 (es) | Derivado de amino-metil piperidina como inhibidor de quinasa | |
| CO2023000396A2 (es) | Nuevo inhibidor de la secreción de ácido y uso del mismo | |
| CL2022003360A1 (es) | Benzofurano, benzopirrol, benzotiofeno sustituidos y otros inhibidores del complemento estructuralmente relacionados (divisional de la solicitud 202002578) | |
| CO2023002852A2 (es) | Péptidos funcionalizados como agentes antivirales | |
| CO2019004004A2 (es) | Composición farmacéutica y método para el tratamiento de la enfermedad del hígado graso no alcohólico | |
| MX2020013297A (es) | Compuestos para el tratamiento o la prevencion de enfermedades hepaticas. | |
| CL2022002641A1 (es) | Agente para el tratamiento de lesión renal aguda inducida por medio de contraste | |
| MX2020004930A (es) | Compuestos de biarilo sustituido novedosos como inhibidores de indolamina 2,3-dioxigenasa (ido). | |
| PH12019502652A1 (en) | 5,6-fused-bicyclic compounds and compositions for the treatment of parasitic diseases | |
| UY38345A (es) | Composición farmacéutica que comprende agente antiplaquetario e inhibidor de la secreción de ácido g | |
| CO4130200A1 (es) | Inhibidores de proteasa del hiv utiles en el tratamiento del sida | |
| AR126552A1 (es) | Composición farmacéutica para prevenir o tratar la esclerosis sistémica | |
| PH12020551117A1 (en) | Compositions for preventing or treating uveitis | |
| CO2019007836A2 (es) | Derivados de pirrolotriazina como inhibidor de cinasas | |
| AR127533A1 (es) | INHIBIDORES DEL SARS-CoV-2 PARA EL TRATAMIENTO DE INFECCIONES POR CORONAVIRUS | |
| AR128051A1 (es) | Inhibidores de parp1 | |
| AR083780A1 (es) | Composicion farmaceutica para tratar infecciones del hcv | |
| CO2022014273A2 (es) | Medicamentos para fibrosis pulmonar que contienen derivado de pirazol | |
| AR124264A1 (es) | Composiciones y métodos para prevenir metástasis cerebrales | |
| CL2023000731A1 (es) | Compuestos para tratar infecciones por virus. | |
| ECSP22030740A (es) | Compuestos y composiciones para el tratamiento de enfermedades parasitarias | |
| AR126393A1 (es) | Terapia combinada para el tratamiento de enfermedades hepáticas |